Free Widgets | Feedback 
Live Share Markets -

Updated:26 May 2017 03:31:00 PM(IST)

Investor Tool

My Stockwatch 

RELIANCE 1337.30 [ +2.68% ]TCS 2578.25 [ -1.77% ]

278.18 0.90%

85.35 0.90%

292.89 2.06%

237.53 1.60%

Bse Corporate Announcements Back
Cipla updates on Stempeutics Research, a JV with Cipla Group
Cipla announced that Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group has been granted a US process patent for its novel stem-cell based drug Stempeucel® by the United States Patent and Trademarks Office (USPTO).

Stempeucel® will initially be used for the treatment of Critical Limb Ischemia (CLI) and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

Market on Mobile

Site Map  •  Mobile  •  Companies  •  Learning Centre  •  Insurance •  About  •  Contact us  •  Disclaimer